Quantum Immunologics Inc is categorized under Commercial Medical Research in Tampa, FL and active since 2008.
Quantum Immunologics Inc was established in 2008, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 541712 by the NAICS.
If you are seeking more information, feel free to contact Charles Broes at the company’s single location by writing to 2202 North West Shore Boulevard, Tampa, Florida FL 33607 or by phoning (813) 785-1130. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Quantum Immunologics Inc |
| Contact Person: | Charles Broes |
| Address: | 2202 North West Shore Boulevard, Tampa, Florida 33607 |
| Phone Number: | (813) 785-1130 |
| Annual Revenue (USD): | $100.000 to $499.999 |
| Founded: | 2008 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2B (Business to Business) |
| Business Category: | Commercial Medical Research |
| SIC Code: | 8731 |
| NAICS Code: | 541712 |
| Share This Business: |
Quantum Immunologics Inc was started in 2008 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.
Feel free to contact Charles Broes for inquiries that concern Quantum Immunologics Inc by calling the company number (813) 785-1130, as your correspondence is most welcome. Additionally, the physical location of the single location of Quantum Immunologics Inc can be found at the coordinates 27.960326,-82.524334 as well as the street address 2202 North West Shore Boulevard in Tampa, Florida 33607.
For its online presence, you may visit Quantum Immunologics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.